Pacira reports preliminary FY2023 revenue of $675.0M, up 1.2% YoY; Q4 EXPAREL sales $143.9M

Pacira BioSciences, Inc.

2023-FY EPS reported $0.89 revenue$674,978,000

FY2023 total revenue $675.0M vs $666.8M in FY2022, driven by EXPAREL ($538.1M), ZILRETTA ($111.1M), iovera° ($19.7M).
Q4 2023 EXPAREL net sales $143.9M (+4.3% YoY); ZILRETTA $28.7M (+2.5%); iovera° $6.0M (+30%).
ExPAREL full-year average daily volume growth of 5%, offset by lower net selling price from 340B and other contracts.
Company plans to launch EXPAREL in two lower extremity nerve blocks in 2024 and expects NOPAIN Act expansion in 2025.
Preliminary, unaudited figures; complete Q4/FY results with 2024 guidance expected in Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pacira BioSciences, Inc. reported full-year ended December 31, 2023 results: revenue $675.0 million.

Period: full-year ended December 31, 2023
Revenue: $675.0 million
Result: preliminary results

Exact text from the filing

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pacira BioSciences, Inc. reported preliminary financial results for fourth quarter ended December 31, 2023.

Period: fourth quarter ended December 31, 2023
Result: preliminary results

Exact text from the filing

On January 4, 2024, Pacira BioSciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.